Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study - Wainberg, ZA; Enzinger, PC; Kang, YK (Lancet Oncol, 2022)
et al.